Funder: National Institutes of Health
Due Dates: June 14, 2025 (New) | July 14, 2025 (Renewal/Resubmission/Revision) | October 17, 2025 (New) | November 17, 2025 (Renewal/Resubmission/Revision)
Funding Amounts: Up to $500,000 direct costs/year (UG3, max 2 years); up to $750,000 direct costs/year (UH3, max 4 years); total project period up to 6 years.
Summary: Supports pragmatic trials to test evidence-based cancer-related interventions across the cancer control continuum, emphasizing health equity and diverse U.S. populations/settings.
Key Information: UG3/UH3 phased cooperative agreement; clinical trial required; milestones must be met for UH3 transition; non-domestic organizations not eligible.